BioNexus Gene Lab Corp. (BGLC) Operating Margin
- Operating margin · 12 months: Value -81.82%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -81.82% | Operating income / revenue. Period ending 2026-06-30. $-2.56M ÷ $3.13M × 100 ≈ -81.82% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -2.56M USD | Operating Income (Loss) |
| Revenue | 3.13M USD | |
| Cost of products and services | (m) | |
| Research and development | 54.13K USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-2.56M | $3.13M | (m) | $54.13K | (m) | -81.82% |
| 2026-03-31 | $-2.89M | $5.31M | (m) | $53.02K | (m) | -54.36% |
| 2025-12-31 | $-2.97M | $7.42M | (m) | $50.67K | (m) | -39.93% |
| 2025-09-30 | $-2.35M | $9.47M | (m) | $56.97K | (m) | -24.81% |
| 2025-06-30 | $-2.98M | $9.55M | (m) | $52.53K | (m) | -31.24% |
| 2025-03-31 | $-2.11M | $9.27M | (m) | $48.17K | (m) | -22.81% |
| 2024-12-31 | $-1.57M | $9.51M | (m) | $47.51K | (m) | -16.55% |
| 2024-09-30 | $-899.73K | $9.26M | (m) | (m) | (m) | -9.72% |
| 2024-06-30 | $-2.09M | $9.18M | (m) | (m) | (m) | -22.77% |
| 2024-03-31 | $-2.62M | $9.78M | (m) | (m) | (m) | -26.82% |
| 2023-12-31 | $-2.59M | $9.77M | (m) | (m) | (m) | -26.54% |
| 2023-09-30 | $-2.97M | $10.34M | (m) | (m) | (m) | -28.77% |
| 2023-06-30 | $-510.73K | $10.36M | (m) | (m) | (m) | -4.93% |
| 2023-03-31 | $-376.50K | $10.28M | (m) | (m) | (m) | -3.66% |
| 2022-12-31 | $-291.18K | $10.93M | (m) | (m) | (m) | -2.66% |
| 2022-09-30 | $32.58K | $11.33M | (m) | (m) | (m) | 0.29% |
| 2022-06-30 | $470.43K | $12.34M | (m) | (m) | (m) | 3.81% |
| 2022-03-31 | $748.42K | $12.94M | (m) | (m) | (m) | 5.78% |
| 2021-12-31 | $1.06M | $13.36M | (m) | (m) | (m) | 7.90% |
| 2021-09-30 | $851.72K | $14.24M | (m) | (m) | (m) | 5.98% |
| 2021-06-30 | $716.39K | $13.76M | (m) | (m) | (m) | 5.21% |
| 2021-03-31 | $542.39K | $11.77M | (m) | (m) | (m) | 4.61% |
| 2020-12-31 | $1.27M | $11.39M | (m) | (m) | (m) | 11.18% |
| 2020-09-30 | $-268.83K | $83.06K | (m) | (m) | (m) | -323.65% |
| 2020-06-30 | $-259.43K | $83.76K | (m) | (m) | (m) | -309.71% |
| 2020-03-31 | $-262.60K | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-275.70K | $126.95K | (m) | (m) | (m) | -217.17% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $59.90K | $212.33K | (m) | (m) | (m) | 28.21% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |